Cost-Effectiveness Colors ACIP Decision On Hep B Vaccination For Diabetics
Executive Summary
The Centers for Disease Control’s Advisory Committee on Immunization Practices limited its Oct. 25 recommendation for vaccinating adult diabetics against hepatitis B to those under 60 years of age because of cost effectiveness considerations.
You may also be interested in...
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP
Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP
Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.
IPAB Members Will Be Named In Time To Begin Recommendations In 2014, Sebelius Says
The White House has begun discussions with potential board member nominees, HHS secretary tells House Energy and Commerce Health Subcommittee.